Forty years of translational cancer research

Cancer Discovery

Volumn 1, Issue 5, 2011, Pages 383-390

  Hait, William N ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANASTROZOLE; BICALUTAMIDE; BIOLOGICAL MARKER; BORTEZOMIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXEMESTANE; FLUTAMIDE; FULVESTRANT; GEFITINIB; IMATINIB; IPILIMUMAB; LETROZOLE; LEUPRORELIN; MONOCLONAL ANTIBODY; NILOTINIB; NILUTAMIDE; PREDNISONE; RITUXIMAB; TAMOXIFEN; TAMOXIFEN CITRATE; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB;

ARTICLE; BREAST CANCER; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TARGETING; ENDOCRINE DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIDRUG RESISTANCE; MYELOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCESS OPTIMIZATION; PROSTATE CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN MANIFESTATION; TRANSLATIONAL RESEARCH; VALIDATION PROCESS; XENOGRAFT;

DRUG DISCOVERY; HUMANS; NEOPLASMS; PROSPECTIVE STUDIES; RESEARCH; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84855865567     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0196     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. National Cancer Institute. Report to nation finds continued declines in many cancer rates;. March 31, 2011. Available from: http://www. cancer.gov/newscenter/pressreleases/2011/ReportNation2011Release.
3. Dimasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 2001;69:286-96.
4. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
6. Hait WN, Hambley TW. Targeted cancer therapeutics. Cancer Res 2009;69:1263-7; discussion
7. Hambley TW, Hait WN. Is anticancer drug development heading in the right direction? Cancer Res 2009;69:1259-62.
8. U.S. Department of Health and Human Services. Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination: Draft Guidance. December 2010. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM236669.pdf.
9. Weinberg RA. The biology of cancer. London: Garland Science, Taylor & Francis Group, LLC; 2007.
10. Sharyl J, Nass HLM, Mendelsohn J. NCI Cooperative Group Program Washington DC.
11. Leaf C. Learning too little, too late: why we need a new paradigm for the cancer clinical; Accelerating Anticancer Agent Workshop, Bethesda, Maryland June 21, 2007.
12. Workman P. How much gets there and what does it do: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
13. Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther 2009;85:134-5.
14. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;16:3299-318.
15. Hong WK, Bast RC Jr, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, et al, editors. Holland-Frei cancer medicine. 8th ed. Shelton (CT): People's Medical Publishing House; 2010
16. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
17. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174-84.
18. Yun CH, Mengwasser KE, Toms AV, Woos MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
19. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
21. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Herman P, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
22. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
23. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007;448:561-6.
24. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2011;363:1693-703.
25. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
26. Robert C, Thomas L, Bondarenko I, O'Day S, MD JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
27. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
28. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
29. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
30. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
31. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73.
32. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
33. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.